Sweden · Investor

HealthCap

Last cheque observed Oct 2026; 32 cheques on record.

Deploying nowNew fund $179M, Jan 2024VC firm

SeedSeries ASeries BLife ScienceTherapeuticsRare Diseases

Deploying now
100%of best year1cheques in 12 months, 32 on record
Since the last cheque17days00hrs00min00sec
Median round$49MCheque size, as they say$100K – $5.0MRounds led1 of 32Sole investor1 roundsExits5 from the portfolioMostly inUnited States, 47%
Pitch HealthCap

HealthCap highlights

  1. 01

    1 cheques in the last 12 months

  2. 02

    Mostly Series B and Series A: 62% of its rounds

  3. 03

    Sole investor in 1 rounds, median $6.8M

  4. 04

    5 exits from the portfolio

What they do

HealthCap is a life science investor and company creator.From their own website
Type
VC firm (from a list, unverified)
Cheque size
$100K – $5.0M as they say
Stages
SeedSeries ASeries BGrowth
Sectors
Life ScienceTherapeuticsRare Diseases
Based in
Stockholm, Sweden
Cold pitches
Not stated

The record

Every round we can evidence, newest first32 appearances

  1. 2026

    1 round

  2. Oct
  3. 2023

    1 round

  4. Feb
    Hemab TherapeuticsSeries B · DK · Firms' own news pages$135MWith 8 others
  5. 2019

    2 rounds

  6. Aug
    Carisma TherapeuticsSeries A · US · Technical$60MWith 1 other
  7. Apr
    Fusion PharamaceuticalsSeries B · CA · FinSMEs$105MWith 11 others
  8. 2018

    4 rounds

  9. Nov
    Aprea TherapeuticsSeries C · US · FinSMEs$57MWith 5 others
  10. Nov
    OncorenaSE · Healthcap$1.6MWith 1 other
  11. Nov
    Camel-IDSSeries A · BE · Healthcap$42MWith 5 others
  12. May
    BioClinSeries B · FinSMEs$20MWith 6 others
  13. 2015

    3 rounds

  14. Jul
    GenSight BiologicsSeries B · FR$36MWith 8 others
  15. Feb
    VaxinVenture · US$16MWith 3 others
  16. Jan
    Strongbridge BiopharmaSE$28MWith 3 others
  17. 2014

    2 rounds

  18. Oct
    Strongbridge BiopharmaGrowth · SE$11MWith 1 other
  19. Apr
    Wilson TherapeuticsSeries B · SE$40MWith 3 others
  20. 2008

    1 round

  21. Nov
    TengionSeries C · US$21MWith 7 others
  22. 2007

    3 rounds

  23. Sept
    NexstimVenture · FI$11MWith 3 others
  24. Jul
    Immune Targeting SystemsSeries A · GB$7.1MWith 3 others
  25. Mar
    CoreValveSeries C · US$33MWith 3 others
  26. 2005

    2 rounds

  27. Feb
    JeriniVenture · DE$20MWith 4 others
  28. Jan
    BiolipoxSeries C$41MWith 5 others
  29. 2004

    5 rounds

  30. Sept
    Sopherion TherapeuticsSeries B · US$47MWith 7 others
  31. Jun
    PTC TherapeuticsSeries E · US$15MWith 9 others
  32. Jun
    JeriniSeries B · DE$38MWith 4 others
  33. Jun
    NucleonicsSeries B · US$49MWith 6 others
  34. Jan
    PTC TherapeuticsSeries E · US$35MWith 8 others
  35. 2003

    4 rounds

  36. Aug
    BioStratumVenture · US$9.5MWith 3 others
  37. Jul
    Bionaut PharmaceuticalsSeries A · US$6.8MSole investor
  38. Mar
    Sopherion TherapeuticsSeries A · US$26MWith 7 others
  39. Jan
    OrexoSeries B · SE$22MWith 4 others
  40. 2002

    1 round

  41. Dec
    RenovoSeries B · GB$33MWith 3 others
  42. 2001

    2 rounds

  43. Dec
    HybrigenicsSeries B · FR$12MWith 7 others
  44. Sept
    PTC TherapeuticsVenture · US$40MWith 9 others
  45. 2000

    1 round

  46. Jun
    HybrigenicsSeries A · FR$8.5MWith 2 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration20 named

AOAlex Ovidiu ValcuPrincipaliForm ADV
AFAnki ForsbergEmployee and Director of the Investment AdvisoriFiling they signed
ACAnn Christine ForsbergDirectoriForm ADV
BOBjorn OdlanderEmployee and Director of the Investment AdvisoriFiling they signed
CKCarl KilanderShareholderiForm ADV
DRDag RichterMember of the Board of DirectorsiFiling they signed
DSDaniel SchaferDirector of the General Partner.iFiling they signed
FBFabrice BernhardMember of the board of directorsiFiling they signed
FKFrancois KaiserMember of the Board of DirectorsiFiling they signed
GBGeorg BeiskeShareholderiForm ADV
HIHealthCap IX Holding ABSole ShareholderiFiling they signed
JGJacob GunterbergEmployee and Director of the Investment AdvisoriFiling they signed
JCJohan ChristensonEmployee and Director of the Investment AdvisoriFiling they signed
KEKristina EkbergDirectoriForm ADV
MSMarile SchiessPrincipaliForm ADV
MSMarten SteenEmployee and Director of the Investment AdvisoriFiling they signed
MOMax OdlanderShareholderiForm ADV
POPer Olof ErikssonDirectoriForm ADV
PSPer SamuelssonEmployee and Director of the Investment AdvisoriFiling they signed
SLStaffan LindstrandEmployee and Director of the Investment AdvisoriFiling they signed

We also hold 31 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$266Mgross assets of its funds, 2 advisers combinedOct 2026
Exemptreporting adviserventure or small private funds
Legal name
Healthcap VIII Advisor AB
SEC number
CRD 305750

What they claim to have backed

From their own portfolio page (on their website)

17 of 24 we have independently watched raise

Adcendo ApSAltay TherapeuticsAprea TherapeuticsAriceum TherapeuticsCurifyLabsDoctrinFusionpharmaGesynta PharmaHelloBetterHemab TherapeuticsIncardatherapeuticsKivu BioscienceMahzi TherapeuticsOncorenaPositrigoPriotheraSpruce BiosciencesAMRA Medical ABBonesupport ABElsa Science ABIntervaccNeobiomicsOncopeptides ABSynOx Therapeutics Ltd

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

Exits from the portfolio

Companies it backed that were later bought or listed5 in all

Immune Targeting SystemsBought by VaxinUndisclosedFeb 2015
PTC TherapeuticsListed$125MJun 2013
TengionListedUndisclosedApr 2010
JeriniBought by Shire$554MJul 2008
BiolipoxBought by OrexoUndisclosedNov 2007

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as HealthCap. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies HealthCap put money into.

Quick answers about HealthCap

What does HealthCap invest in?

HealthCap invests most often at Series B and Series A (62% of the rounds on record), in sectors such as Life Science, Therapeutics and Rare Diseases.

How active is HealthCap?

32 investments on record, 1 of them in the last 12 months, and it led 1. The most recent was in Oct 2026.

What has HealthCap invested in recently?

Its most recent investments on record: Altay Therapeutics, Inc. (Series A, Oct 2026), Hemab Therapeutics (Series B, Feb 2023) and Carisma Therapeutics (Series A, Aug 2019).

How big are HealthCap's cheques?

The median round it joins is $49M. It says it writes cheques of $100K to $5.0M.

Does HealthCap lead rounds?

Sometimes: it led 1 of its 32 investments on record (3%).

Where does HealthCap invest?

Most of the companies it backs are in the United States (47%), Sweden (17%) and France (10%).

Is HealthCap investing now?

Yes: it is actively investing, with 1 investments in the last 12 months.

Who does HealthCap invest alongside?

Most often Apax Partners (4 rounds together), Auriga Partners (4 rounds together) and Bay City Capital (3 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it